Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 EUR | -0.32% | -6.20% | -9.49% |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 3.55 times its current sales, is high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.49% | 134M | C+ | ||
-3.26% | 102B | B+ | ||
+1.70% | 96.29B | B+ | ||
+2.13% | 22.18B | B | ||
-15.73% | 21.2B | B+ | ||
-9.21% | 18.31B | A- | ||
-39.98% | 17.38B | A- | ||
-14.63% | 16.36B | B | ||
+5.84% | 13.97B | C+ | ||
+33.82% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TNG Stock
- Ratings Transgene